Início › Linfoma Difuso de Grandes Células B › Carolina do Norte
Ensaios clínicos de Linfoma Difuso de Grandes Células B em Carolina do Norte
20 estudos para Linfoma Difuso de Grandes Células B estão buscando participantes em locais em Carolina do Norte.
Cidades em Carolina do Norte
Texto oficial do estudo (Inglês)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Duke University Medical Center, Durham
- East Carolina University, Greenville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of North Carolina Medical Center ( Site 0136), Chapel Hill
- Novant Health Presbyterian Medical Center ( Site 0177), Charlotte
- Novant Health Forsyth Medical Center ( Site 0206), Winston-Salem
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- East Carolina University ( Site 0159), Greenville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06717347Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Novant Health Cancer Institute- Hematology, Charlotte
- Duke Blood Cancer Center, Durham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT06500273A Study of ARC-02 in B-cell NHL
- Levine Cancer Institute, Charlotte
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Atrium Health Wake Forest Baptist, Winston-Salem
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
RecrutandoFase 1/2
Idades de 13 a 90 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT04792489Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Wake Forest University Health Sciences, Winston-Salem
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de jul. de 2026 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de jul. de 2026 · NCT05131022Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- e mais 4
RecrutandoEstudo observacional
Idades 65 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT01137825Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Duke Univerisity, Durham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 13 de fev. de 2026 · NCT04775745Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Wake Forest University Health Sciences, Winston-Salem
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de fev. de 2026 · NCT05633615Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecrutandoEstudo observacional
Idades de 18 a 120 · Todos os sexos · Atualizado em 27 de out. de 2025 · NCT01137643A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2025 · NCT05780034A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2025 · NCT05107674Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 26 de set. de 2024 · NCT06238648DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Brody School of Medicine at East Carolina University, Greenville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 7 de abr. de 2023 · NCT04920617Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.